Disc Medicine plans FDA filing after positive bitopertin Phase 3 data
The company reported lower PPIX levels and more pain-free light exposure, and plans a new FDA submission by year-end.
Makkler Newsroom · Oct 20, 03:14 PM · 1 min read
Market closed· · USD · Data may be delayed
Avg. target $126.77 (+65.5%)
Prices may be delayed and are for informational purposes only - not investment advice.
Profitability and valuation from the filed statements
Answers from price, statements, peer and news data. Not investment advice.
MakklerAI Q&A is open to MakklerPRO members. Upgrade to MakklerPRO